Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease

(2018) C. D. Binde et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Safinamide: a new hope for Parkinson’s disease?

(2018) Fábio G. Teixeira et al.   DRUG DISCOVERY TODAY

MAO inhibitors and their wider applications: a patent review

(2018) Simone Carradori et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease

(2018) Hailin Zheng et al.   JOURNAL OF ALZHEIMERS DISEASE

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence

(2018) Sagari Bette et al.   Therapeutics and Clinical Risk Management

Tranylcypromine in mind (Part I): Review of pharmacology

(2017) Sven Ulrich et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

(2017) Thomas Müller   Expert Opinion on Drug Metabolism & Toxicology

Major depression and heart failure: Interest of monoamine oxidase inhibitors

(2017) Sophie Corbineau et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Monoamine Oxidase A Gene Methylation and Its Role in Posttraumatic Stress Disorder: First Evidence from the South Eastern Europe (SEE)-PTSD Study

(2017) Christiane Ziegler et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis

(2017) Makoto Naoi et al.   JOURNAL OF NEURAL TRANSMISSION

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

(2017) Tamar Amit et al.   NEUROPHARMACOLOGY

A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice

(2016) Sagit Golko-Perez et al.   NEUROTOXICITY RESEARCH

MAOA gene hypomethylation in panic disorder—reversibility of an epigenetic risk pattern by psychotherapy

(2016) C Ziegler et al.   Translational Psychiatry

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis

(2015) Chris Stinton et al.   AMERICAN JOURNAL OF PSYCHIATRY

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging

(2015) Orit Bar-Am et al.   NEUROBIOLOGY OF AGING

Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response

(2014) Katharina Domschke et al.   JOURNAL OF NEURAL TRANSMISSION

Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations

(2012) Andreas Reif et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

The Novel Multi-Target Iron Chelating-Radical Scavenging Compound M30 Possesses Beneficial Effects on Major Hallmarks of Alzheimer's Disease

(2012) Lana Kupershmidt et al.   ANTIOXIDANTS & REDOX SIGNALING

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

(2012) Orly Weinreb et al.   CURRENT DRUG TARGETS

Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice

(2012) Lana Kupershmidt et al.   MOLECULAR NEUROBIOLOGY

Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease

(2011) Anthony H.V. Schapira   CNS DRUGS

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain

(2011) L. Kupershmidt et al.   NEUROSCIENCE

MAO-inhibitors in Parkinson's Disease

(2011) Peter Riederer et al.   Experimental Neurobiology

Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities

(2010) Orly Weinreb et al.   ANTIOXIDANTS & REDOX SIGNALING

Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

(2009) Shunit Gal et al.   NEUROTOXICITY RESEARCH

Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs

(2008) Orly Weinreb et al.   Neurotherapeutics

Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

(2007) Tamar Amit et al.   FASEB JOURNAL